Propranolol in Angiosarcoma

Status Completed

Clinical Trial Summary

This is a window opportunity study of propranolol in patients with angiosarcoma. The aim of this study is to prospectively evaluate the activity of propranolol in the clinical setting as monotherapy, where the neoadjuvant setting provides a good opportunity to rapidly evaluate both the clinical response and histological response, without a significant delay in anti-cancer treatment.

Clinical Trial Description

A pilot neoadjuvant window of opportunity study will be performed to explore the activity of propranolol monotherapy in angiosarcoma. The study consists of a single arm. Propranolol will be administred as monotherapy in a dose of 40-80 mg 2-3 times a day, if tolerated. When patients are diagnosed, standard anti-cancer treatment will be scheduled in 6 weeks while propranolol treatment can start immediately after diagnosis and will be continued until the day the standard anti-cancer treatment is started. The duration of treatment will therefore be 3-6 weeks. ;

Study Design

Related Conditions & MeSH terms

Angiosarcoma

Clinical Trial Details

NCT number	NCT04518124
Study type	Interventional
Source	The Netherlands Cancer Institute
Contact
Status	Completed
Phase	Phase 2
Start date	December 27, 2019
Completion date	October 30, 2023

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT04906876` - A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas	Phase 2
Completed	`NCT01303497` - Efficacity of Weekly Paclitaxel in Association or Not With Bevacizumab in Metastatic or Locally Advanced Angiosarcomas	Phase 2
Recruiting	`NCT02625389` - Evaluation of Lipiodol® Ultra Fluid in Association With Surgical Glues During Vascular Embolization.	Phase 4
Completed	`NCT04293289` - Boron Neutron Capture Therapy Using CICS-1 and SPM-011 for Malignant Melanoma and Angiosarcoma	N/A
Recruiting	`NCT05859074` - A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer	Phase 1
Not yet recruiting	`NCT02732678` - Dose-Finding of Propranolol in Combination With Metronomic Fixed Oral Cyclophosphamide Based on Bivariate Efficacy-tolerability Outcome in Patients With Locally Advanced or Metastatic Angiosarcoma: A Collaborative and Innovative Phase I-II Sequential Trial by the French Sarcoma Group (GSF/GETO)	Phase 1/Phase 2
Recruiting	`NCT04055220` - Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas	N/A
Recruiting	`NCT06375941` - Prospective Observational Study of Localized Angiosarcoma of Any Site: ProStars
Recruiting	`NCT05799612` - Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma	Phase 1
Withdrawn	`NCT05116800` - Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma	Phase 2
Recruiting	`NCT01042379` - I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer	Phase 2
Active, not recruiting	`NCT01786889` - Identification, Molecular Epidemiology Angiosarcoma of the Liver France	N/A
Terminated	`NCT02212015` - Evaluation of Votrient in Angiosarcoma	Phase 2
Active, not recruiting	`NCT02834013` - Nivolumab and Ipilimumab in Treating Patients With Rare Tumors	Phase 2
Active, not recruiting	`NCT03331250` - Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)	Phase 2
Completed	`NCT02584309` - Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma	Phase 2
Not yet recruiting	`NCT06277154` - MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma	Phase 2
Withdrawn	`NCT04607200` - AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma	Phase 2
Recruiting	`NCT05961761` - Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients	Phase 2
Completed	`NCT00887809` - Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes	Phase 2